Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
oremepermin alfa (オレメペルミン アルファ, recombinant human dHGF protein)
Applicable field (uses covered by this announcement)
Commercialization of pharmaceuticals, medical devices and regenerative medicine products; treatment of rare diseases
Launch date7 to 9 October 2026 (scheduled exhibition)
Location (as indicated in this announcement)
Pacifico Yokohama (exhibition venue)
Booth No. V-86
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Ministry of Health, Labour and Welfare; JHVS 2026 official website
| Item | Details |
|---|---|
| Names of Products / Services Covered | oremepermin alfa (オレメペルミン アルファ, recombinant human dHGF protein) |
| Launch date | 7 to 9 October 2026 (scheduled exhibition) |
| Applicable area | Commercialization of pharmaceuticals, medical devices and regenerative medicine products; treatment of rare diseases |
| Location | Pacifico Yokohama (exhibition venue) |
| Location scale | Booth No. V-86 |
| Source | Ministry of Health, Labour and Welfare; JHVS 2026 official website |
Items this document does not state (12)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish contacts with parties interested in business alliances, joint research, licensing and investment.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.